Clinical response rate and flares of hidradenitis suppurativa in the treatment with adalimumab.
Hidradenitis suppurativa/acne inversa (HS) is a chronic, inflammatory, skin disease. Adalimumab is the only approved drug for the treatment of hidradenitis suppurativa (HS), but it only partially controls the symptoms. Evaluate the incidence of flares during 108 weeks of therapy and the clinical response to Adalimumab. Twenty patients with moderate-severe HS treated with Adalimumab were included to evaluate the number of flares, average interval of time among flares, number of patients who reached the Hidradenitis Suppurativa Clinical Response (HiSCR), IHS4, pain VAS, lesions count and DLQI assessment. 90% of patients reported at least 1 flare and a total of 48 flares were counted in all patients; average time between flares was 26.9±16.4 weeks. In particular, duration between flares was 30.5±16.3 and 12.5±5.7 respectively in responders and non-responders. A progressive decline of flares was observed, while a gradual increase in the number of patients achieving HiSCR was attained during the observational period. Lesions count, IHS4, pain VAS and DLQI decreased throughout the study. In detail, Adalimumab showed a higher efficacy on nodules-abscesses than on draining tunnels. The study had a retrospective nature and a small number of patients. Adalimumab is an effective and safe treatment for HS patients despite the high number of flares.